28 results about "Sphingolipid" patented technology

The present invention provides the use of at least one sphingolipid for a hair treatment for inducing hair growth and / or inhibiting hair loss, including eyelashes and eyebrows. Said sphingolipid is preferably a ceramide having a fatty acid with a long hydrocarbon chain of C18-C24, mostly C20-C22, and a phytosphingosine base. Furthermore, and advantageously, the treatment is global, capable to also improve the properties of the scalp and hair themselves.

This invention provides a sea cucumber ganglioside extract nanoliposome with neuroprotective activity and its preparation method. The preparation steps are as follows: thawed frozen ready-to-eat sea cucumber, chopped, freeze-dried, pulverized, and sieved to obtain freeze-dried powder. The powder is then extracted using supercritical CO2 extraction and rotary evaporation to remove the solvent. This powder is then dissolved in anhydrous ethanol with soybean lecithin and β-sitosterol as the oil phase, mixed with PBS buffer, stirred, and hydrated to obtain a proemulsion. After centrifugation, the precipitate is resuspended and sonicated to obtain the product. This invention uses supercritical CO2 extraction, and the extract contains 59.70 μg / g of gangliosides, with glycosphingolipids accounting for 96.372% of sphingolipids, resulting in enrichment of the target components. Simultaneously, these nanoliposomes significantly delay Aβ1-42-induced paralysis. The 30 μg / mL group showed a 2.75-fold increase in motor ability and a 30% increase in reproductive function compared to the control group, and a 47% reduction in ROS levels. The neuroprotective effect is superior to that of the unencapsulated extract, providing a new approach for adjuvant intervention in neurodegenerative diseases such as Alzheimer's disease, and has broad application prospects in the functional food field.

The invention discloses lipidosome, a medicine lipidosome compound and a preparation method and application of the medicine lipidosome compound. The liposome comprises the following components in parts by mass: 10-65 parts of saturated phospholipid; 25 to 75 parts of unsaturated phospholipid; 0.5 to 15 parts of a trigger lipid; the trigger lipid is sphingolipid and / or cholesterol; the mass ratio of the saturated phospholipid to the unsaturated phospholipid is (0.20-2.50): 1. When the lipidosome is used for drug encapsulation, high encapsulation efficiency can be guaranteed, high activity of drugs can be maintained, the lipidosome can be stably stored, and a universal carrier is provided for drugs with different physicochemical properties (especially highly hydrophilic drugs, such as protein drugs and nucleic acid drugs).

The present invention relates to a lipid system comprising: a) at least one oil, b) at least one ionizable lipid, c) at least one sphingolipid, and d) at least one lipid-polymer, with the proviso is that the lipid system does not comprise cholesterol. The present invention also uses of the lipid system in therapy.

In various embodiments, host cells, methods, and pharmaceutical compositions comprising complex sphingolipids such as monosialoganglioside 1 (GM1), monosialoganglioside 2 (GM2), and monosialoganglioside 3 (GM3) are provided herein. In some embodiments, the disclosure provides the bioproduction of sphingoglycolipids. In yet another embodiment, the disclosure provides the bioproduction of gangliosides.

The application of ceramide in the control of rice blast fungus falls within the field of biological control. This invention relates to the application of ceramide in the control of rice blast fungus: a combination of ceramide and lipopeptides is used for the control of rice blast fungus. Exogenous addition of ceramide significantly enhances the stress effect of lipopeptides on rice blast fungus. It also enhances the abnormal accumulation of glycogen and lipid droplets in conidia, promotes the bursting of ROS, and increases intracellular ceramide and calcium... 2+ The invention increases the content of malondialdehyde (MDA) in mycelium, enhances membrane lipid peroxidation, and decreases ergosterol content. Furthermore, it inhibits the expression of ergosterol synthesis genes, UPR target genes, and sphingolipid metabolism-related genes. This invention develops a highly efficient natural agent against rice blast by combining exogenous Cer with lipopeptides. This agent effectively reduces the pathogenicity of rice blast fungus and significantly inhibits its infection of rice, laying the foundation for the development of novel biological control agents.

The application provides application of pig's tooth saponin volatile oil in preparation of a medicine for treating cerebral ischemia-reperfusion injury, and a preparation method of the pig's tooth saponin volatile oil is as follows: pig's tooth saponin decoction pieces are taken, water and n-hexane are added, and volatile oil is obtained through steam distillation; the volatile oil is collected, anhydrous sulfuric acid is added, and water is removed; and the mixture is left overnight to obtain the pig's tooth saponin volatile oil. The prepared pig's tooth saponin volatile oil acts on key target points of VEGFA, SRC, MAPK8, PIK3CA and TNF through active ingredients of paeonol, linalool, methyl eugenol, anethole and eugenol, regulates multiple signal pathways of sphingolipids, TNF and VEGF, inhibits cell oxidative stress injury, inhibits release of inflammatory factors and regulates nerve function, so as to play a role in treating cerebral ischemia-reperfusion injury, and lay a foundation for further in-depth study on a treatment mechanism of pig's tooth saponin in treating 'opening the orifices and connecting the heart and the lung'.

Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

The present disclosure pertains to the use of an Anc80 viral vector that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the Anc80 vector reduces high levels of ceramide in the cell that lead to cell death or senescence.

The invention discloses a formula of medicinal and edible rice paste capable of tonifying spleen, clearing damp and preventing encephalatrophy. Comprising the following components: 10-20 parts of soybeans, 8-15 parts of small red beans, 6-12 parts of fried coix seeds (fried until the surfaces are light golden yellow and have no burnt spots), 5-10 parts of Chinese yams, 4-8 parts of white poria cocos, 3-7 parts of radix puerariae, 3-6 parts of fried gordon euryale seeds (the frying standard is that the surfaces are slightly burnt and have light burnt fragrance, and the particle size is 2-3mm), 2-5 parts of dried longan, 15-25 parts of millet and 0.5-1.5 parts of shredded dried tangerine peels. The invention belongs to the technical field of medicinal and edible foods, and particularly relates to a medicinal and edible rice paste formula for tonifying spleen, clearing damp and preventing encephalatrophy.

Provided herein are sphingolipid-loaded nanobiologics and uses thereof e.g., in innate immune regulation and the treatment of cancer.

The invention discloses a sphingolipid ceramide N-deacylase mutant. The mutant is formed by amino acid mutation in sphingolipid ceramide N-deacylase as shown in SEQ ID NO.1, and the amino acid mutation is selected from one or more of mutation of the 232 site Tyr, mutation of the 254 site Asn, mutation of the 416 site Phe and mutation of the 592 site Leu. The invention also discloses application of the mutant in preparation of ganglioside derivative molecules by efficient enzymatic synthesis. The stability of the sphingolipid ceramide N-deacylase SCDase mutant is improved, and the pyrolysis chain temperature Tm of the mutant is improved by 5.79 DEG C compared with that of a wild type; the sphingolipid ceramide N-deacylase SCDase mutant provided by the invention enhances the enzyme preparation efficiency of ganglioside, especially for short-chain fatty acids (carbohydrate chain length lt; and 4) the synthetic activity is improved by more than two times, and the result broadens the practical application value of the SCDase enzyme.

A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid an

This invention discloses a polysaccharide extracted from *Gynostemma pentaphyllum* using ultrasound-assisted extraction, its preparation method, and its applications, belonging to the field of biomedical technology. This polysaccharide significantly improves peripheral blood counts in mice with cyclophosphamide-induced anemia, alleviates immune organ atrophy and liver damage, and its mechanism of action involves regulating the intestinal flora structure and modulating host sphingolipid and glycerophospholipid metabolic pathways. The preparation method efficiently yields homogeneous polysaccharides from *Gynostemma pentaphyllum*, with optimized process conditions of a liquid-to-solid ratio of 32 mL / g, extraction time of 48 min, and temperature of 60 ℃. The process of this invention is stable and provides a new candidate substance for developing drugs or health foods for the prevention and treatment of chemotherapy-related anemia.

The present invention relates to a blend comprising fatty acids and / or lipids such as sphingolipids, wherein the blend comprises C in an amount between approximately 0.5 and 30 wt%. 22 -C 38 The present invention also relates to compositions containing aliphatic alcohols and lipid blends. The present invention further provides a method for producing the lipid blend on a large scale, wherein rice bran wax (RBW) is used as a source of fatty acids.

The present invention provides: a novel sphingolipid which is in liquid form at room temperature due to a low melting point, and which blends easily with a variety of vegetable and / or animal oils; and a dermatologic composition for external application comprising the novel sphingolipid.

The invention belongs to the technical field of biomedical detection, and particularly relates to a metabolite composition for curative effect prediction and progress risk dynamic monitoring of esophageal squamous cell carcinoma treatment-free combination therapy and application. According to the method, a targeted detection panel containing 1384 metabolites is constructed, and on the basis of plasma samples of 541 patients and an external verification queue, an esophageal squamous carcinoma treatment whole-course large-scale metabonomics dynamic database and a multi-model prediction system are established for the first time; a developed complete cycle scheme comprises a high-precision baseline prediction model (AUC 0.864-0.999) based on 23 markers, a curative effect prediction model (AUC 0.773-0.885) for identifying 25% of long-term benefit people, and a progress risk early warning model based on a sphingolipid and glycerophospholipid yin-yang balance mechanism. The multi-model integration system is verified by an independent queue, and a first non-invasive and accurate plasma metabonomics dynamic monitoring scheme is provided for ESCC individualized treatment.

A method for production of at least one sphingolipid of formula (1), or a composition thereof. The method comprising reacting at least one lysosphingolipid of formula (2), or a salt thereof: with a compound of formula (3): wherein W, R1, R2, R3, and R4 are as defined as for the sphingolipid of formula (1), and wherein, said reacting is performed in the presence of a base of formula (4): wherein n is 1, 2, or 3; m is 1 or 2; X is selected from Na+, K+, NH4 +, Mg2+, or Ca2+; Y is selected from OH-, CO3 2-, HCO3 -, PO4 3-, methoxide, acetate, citrate, or succinate.

The invention provides a pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. The sphingolipid metabolite is added in the immune cell in-vitro culture process, the immune cell function is remodeled in a metabolic regulation mode, and the dryness and tumor killing capacity of the immune cells are remarkably enhanced.

The invention belongs to the technical field of microorganisms, and particularly relates to sphingobium sp., a microbial preparation of the sphingobium sp. And application of the sphingobium sp. The new sphingolipid strain D-491 is separated and screened from the desert environment, has the functions of nitrogen fixation, IAA secretion, alkali stress resistance and the like, enriches microbial strain resources and genome information, and broadens the application scene of the sphingolipid strain.

The present invention provides an anhydrous formulation composition comprising bakuchiol and sphingolipid, and a composition for improving skin irritation of bakuchiol comprising sphingolipid as an active ingredient. Specifically, the anhydrous formulation composition of the present invention may improve skin irritation caused by bakuchiol while maintaining excellent effects of bakuchiol by including sphingolipid.

The invention belongs to the technical field of microbial agents, and provides a methyl nutrition complex microbial inoculant and an application thereof in rice methane emission reduction, and the complex microbial inoculant comprises facultative methylobacterium, sphingobacterium, escherichia coli, variovorax, flavobacterium, sphingolipid, pseudoyellow microbacterium, Knoobrucella, sedimentary bacillus and terranean bacillus. The complex microbial inoculant disclosed by the invention can effectively reduce methane emission in rice planting, and has the functions of reducing emission, improving efficiency and promoting stable yield.

Various oil-in-water (O / W) nanoemulsions containing an oil phase or oil core, preferably selected from vitamin E or oleic acid, stabilized by a sphingolipid of the sphingomyelin type, and optionally other lipids such as phospholipids, cholesterol, octadecylamine, DOTAP (N-[1-(2,3-Dioleoyloxy) propyl]-N,N,N-trimethylammonium methyl-sulfate), and PEGylated derivatives (derivatives with polyethylene glycol), for use as a nanotech vehicle, for example for the management of cancer and metastatic disease. Said nanoemulsions can be functionalized with ligands capable of interacting or binding to receptors expressed on the cell membrane of tumor cells, and in particular capable of interacting or binding to receptors expressed on the membrane of primary and / or disseminated or metastatic tumor cells. Also, antitumor drugs or therapeutic biomolecules can be encapsulated in said nanoemulsions and, finally, contrast agents can be incorporated for their use in the in vivo diagnosis in said nanoemulsions.

The application provides a lysophosphatidylcholine (LPC) kit with anti-coccidiosis effect, and discloses a diagnosis marker for Eimeria tenella infected chicken, which is characteristic phospholipid and sphingolipid molecules, and specifically phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM). Meanwhile, the application provides a medicine composition for improving the survival rate of chicks infected with Eimeria tenella, which is characterized by containing effective amounts of 18:2 LPA, 18:1 LPC, 22:0 LPC, 16:0 18:1 PC, 16:0 18:2 PC and d18:1 16:0 SM. The application screens characteristic phospholipid and sphingolipid molecules in the cecum tissue of chicken infected with Eimeria tenella for the first time, and verifies the curative effect of phosphatidylcholine (PC), lysophosphatidylcholine (LPC) and sphingomyelin (SM) on acute infection of chicks with Eimeria tenella, which has great market development prospect.

A composition for skin application and uses thereof are disclosed. The composition includes a sphingolipid containing a salicylic acid derivative as an active ingredient. The composition including a sphingolipid containing a salicylic acid derivative may exhibit, when applied to the scalp, an effect of alleviating scalp erythema, an effect of increasing the amount of moisture in the scalp, an effect of inhibiting scalp sebum secretion, an effect of inhibiting scalp itchiness, and the like.

Provided herein are compositions and methods for the delivery of prosaposin and saposins within the tumor microenvironment in order to enhance anti-tumor immunity.

The invention relates to the technical field of metabolite evaluation, in particular to a plasma metabolite evaluation method and system for a patient with x-adrenal leukodystrophy. The method comprises the following steps: acquiring a patient plasma information set, and analyzing dynamic change information of fatty acid and cholesterol in plasma metabolites based on the patient plasma information set to obtain a dynamic track information set; acquiring a patient condition information set, and analyzing associated risk information of neurotoxic sphingolipid accumulation and oxidative stress level increase based on the patient condition information set in combination with the dynamic trajectory information set to obtain a damage associated information set; and acquiring an individual information set of the patient, analyzing the dynamic influence of age and gender data on the illness state based on the individual information set of the patient in combination with the injury associated information set, obtaining an individualized illness state information set, and outputting a plasma metabolite evaluation log. A solid foundation is laid for accurately identifying the neurotoxicity risk and formulating an individualized diagnosis and treatment scheme, and the scientificity and clinical application value of the overall evaluation method are improved.